Anti-GARP:TGF-β1 mAbs could thus be tested in the clinics to overcome resistance to PD-1/PD-L1 blockade in patients with a broad range of cancer types, including not only tumors already infiltrated by T cells, but also poorly vascularized tumors with low immune cell infiltration. The gene discussed is CD274; the disease is cancer.